ArticleScientific reports2025
The role of PAX1 and JAM3 methylation in predicting the pathological upgrading of cervical intraepithelial neoplasia before conization.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- PAX1/JAM3 methylation-a novel biomarker for early detection and accurate management of cervical adenocarcinoma.American journal of cancer research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
To explore the effect of PAX1 and JAM3 gene methylation on pathological upgrading before conization. A total of 549 patients who underwent colposcopy at our hospital were enrolled for analysis from December 2020 to April 2022. PAX1 and JAM3 gene methylation results in preoperative cervical exfoliated cells were collected. Univariate analysis and multivariate logistic regression analysis were conducted to identify the independent risk factors influencing the pathological upgrading of conization, aiming to establish a prediction model. A total of 88 patients were finally included for statistical analysis according to the inclusion and exclusion criteria. Based on univariate analysis and multivariate logistic regression analysis, ∆Ct PAX1 (P = 0.016, OR: 0.784, 95%CI 0.644-0.956) and cervical canal lesions (P = 0.048, OR: 3.469, 95%CI 1.014-11.870) were identified as independent risk factors for pathological upgrading for conization. Using the above results, we established a prediction model for pathological upgrading and plotted the receiver operator characteristic curve (ROC). The area under the curve (AUC) was calculated when the Youden index was maximized with an AUC value of 0.818 (95%CI 0.720-0.916), specificity of 94.4%, sensitivity of 60%. The cut-off value for ∆Ct PAX1 was determined as 4.34 when maximizing the Youden index. PAX1 could be a promising triage marker in predicting the pathological upgrading of CIN before conization. We found that if the ∆Ct PAX1 cut-off value is lower than 4.34, it is highly suggestive of pathological upgrading.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.